Translational Insights on Genomic Status and Biomarker Modulation Using OncoPanel and BioMAP Platforms

Translational Insights on Genomic Status and Biomarker Modulation Using OncoPanel and BioMAP Platforms
Version:
21316

File Name/Number:
AACR

Year:
2022

 

Trastuzumab (Herceptin®), a humanized monoclonal antibody (mAb) targeted against the ErbB2 protein, was approved by the FDA in 1998 and the EMA in 2000 to treat Her2-positive breast cancer, and in 2010 received FDA approval for the treatment of Her2-positive gastric cancer. As of April 2021 there were five biosimilars for trastuzumab with regulatory approval.